MM-121 + Paclitaxel

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,

Conditions

Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer

Trial Timeline

Oct 1, 2010 → Jul 1, 2014

NCT ID

NCT01209195

About MM-121 + Paclitaxel

MM-121 + Paclitaxel is a phase 1 stage product being developed by Sanofi for Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,. The current trial status is completed. This product is registered under clinical trial identifier NCT01209195. Target conditions include Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer, were approved

Approved (5) Terminated (1) Active (14)

✅letrozoleJiangsu Hengrui MedicineApproved

✅FulvestrantAstraZenecaApproved

✅PazopanibNovartisApproved

✅LetrozoleNovartisApproved

✅Trastuzumab emtansineRocheApproved

🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01447706	Phase 2	Completed	Oct 1, 2011	Jun 1, 2015	Epithelial Ovarian Cancer
NCT01421472	Phase 2	Completed	Aug 1, 2011	Jun 1, 2014	ER Positive, Her2 Negative Breast Cancer Patients
NCT01209195	Phase 1	Completed	Oct 1, 2010	Jul 1, 2014	Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,

Competing Products

20 competing products in Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,

See all competitors

Product	Company	Stage	Hype Score
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	35
NBTXR3	Nanobiotix	Phase 1/2	33
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	29
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 1	36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	39
zolbetuximab	Astellas Pharma	Pre-clinical	30
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	39
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44
enfortumab vedotin (EV)	Astellas Pharma	Pre-clinical	26
zolbetuximab	Astellas Pharma	Pre-clinical	33
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	44
ASP3082	Astellas Pharma	Phase 2	42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	47
ASP1948	Astellas Pharma	Phase 1	29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )	Sun Pharmaceutical	Phase 2	31